Abstract
I have been studying AMR mechanisms for over 25 years, and publishes regularly in Nature and Lancet journals. I am director of BARNARDS, a Gates Foundation project on AMR, prospectively examining the burden of neonatal sepsis in Pakistan, India, Bangladesh, Rwanda, South Africa, Nigeria (Abuja and Kano) and Ethiopia. Follow up programs include assessing the risks of still-born infants and maternal care in sub-Sahara Africa and assessing the impact of access to affordable antibiotics. Studies in Pakistan include the role of insects in post-surgical infections and the illegal global trade of colistin in agriculture. In addition to BARNARDS, he also has AMR studies in Karachi and Peshawar and has collaborative studies with MSF in Niger (Clean Kids Study) and has facilitated the design and construction of the MSF Microbiology/AMR lab in Jordan/Syria. I also have clinical studies examining the burden of AMR in the community and hospitals San Paolo (Brazil), Phitsanulok (Thailand) and Tanta (Egypt).I am also PI of DETER-XDR-CHINA, a study examining the spread and burden of AMR in public health sectors and hospitals in 30 provinces in China. I hold an honorary chair at the Chinese Agricultural University and is an AMR advisor to the Chinese. I am also PI of CUT-SEC, a ‘one-health” project in China and Thailand.
Recently, I moved to University of Oxford, and established the Ineos Oxford Institute of Antimicrobial Research (£100M gift from Ineos) where I became Co-Director and Biology Lead. I was also appointed to the Fleming Fund expert advisory panel – a rolling UK government AMR capacity building program in LMICs. I am also advisor to the Chinese CDC and MSF and has recently been appointed on the WHO Strategic and Technical Advisory Group for Antimicrobial Resistance (STAG-AMR). In 2020, I was awarded an O.B.E for “Microbiology and International Development”.
Date of Award | 27 Sept 2022 |
---|---|
Original language | English |
Awarding Institution |
|
Supervisor | Nick A Maskell (Supervisor) |
Keywords
- Antibacterial antibiotics
- neonatal sepsis
- one-health